William Deraedt
Overview
Explore the profile of William Deraedt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
3183
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Cohen A, Mateos M, Cohen Y, Rodriguez-Otero P, Paiva B, van de Donk N, et al.
Blood
. 2022 Sep;
141(3):219-230.
PMID: 36095849
B-cell maturation antigen (BCMA)-targeting therapies, including bispecific antibodies (BsAbs) and antibody-drug conjugates (ADCs), are promising treatments for multiple myeloma (MM), but disease may progress after their use. CARTITUDE-2 is a...
12.
Weisel K, Krishnan A, Schecter J, Vogel M, Jackson C, Deraedt W, et al.
Clin Lymphoma Myeloma Leuk
. 2022 Jun;
22(9):690-701.
PMID: 35764490
Introduction: This study estimated the comparative efficacy of ciltacabtagene autoleucel (cilta-cel; CARTITUDE-1), a chimeric antigen receptor (CAR)-T-cell therapy, versus 3 non-CAR-T therapies (belantamab mafodotin [DREAMM-2], selinexor plus dexamethasone [STORM Part...
13.
Martin T, Usmani S, Berdeja J, Agha M, Cohen A, Hari P, et al.
J Clin Oncol
. 2022 Jun;
41(6):1265-1274.
PMID: 35658469
Purpose: CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory multiple myeloma, yielded early, deep, and durable responses at...
14.
Crawford R, Gries K, Valluri S, Fastenau J, Morrison R, Yeh T, et al.
Cancer Rep (Hoboken)
. 2022 Feb;
5(11):e1603.
PMID: 35168299
Background: Relapsed refractory multiple myeloma (RRMM) is a disease that is nonresponsive or progressive on therapy, and although patients can achieve remission, relapse is common. As more treatment options become...
15.
Jakubowiak A, Usmani S, Krishnan A, Lonial S, Comenzo R, Wang J, et al.
Clin Lymphoma Myeloma Leuk
. 2021 Jul;
21(10):701-710.
PMID: 34274290
Background: Combination therapy regimens containing a proteasome inhibitor, an immunomodulatory drug, and a steroid are an established standard of care for patients with newly diagnosed multiple myeloma (NDMM) regardless of...
16.
Martin T, Usmani S, Schecter J, Vogel M, Jackson C, Deraedt W, et al.
Curr Med Res Opin
. 2021 Jul;
37(10):1779-1788.
PMID: 34256668
Objective: This study estimated the comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus the approved idecabtagene vicleucel (ide-cel) dose range of 300-460 × 10 CAR-positive T-cells for the treatment of patients...
17.
Berdeja J, Madduri D, Usmani S, Jakubowiak A, Agha M, Cohen A, et al.
Lancet
. 2021 Jun;
398(10297):314-324.
PMID: 34175021
Background: CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation antigen-targeting single-domain antibodies, in patients with...
18.
Cavo M, Dimopoulos M, San-Miguel J, Mateos M, Jakubowiak A, Deraedt W, et al.
Clin Lymphoma Myeloma Leuk
. 2020 Apr;
20(7):480-489.
PMID: 32278674
Introduction: Bortezomib, melphalan, and prednisone (VMP) is the standard of care for transplant-ineligible newly diagnosed multiple myeloma. The phase III VISTA trial established the bortezomib dosing schedule for VMP. To...
19.
Xu X, Moreau P, Usmani S, Lonial S, Jakubowiak A, Oriol A, et al.
Adv Ther
. 2020 Feb;
37(4):1464-1478.
PMID: 32078124
Introduction: Daratumumab, a human immunoglobulin Gκ monoclonal antibody targeting CD38, is approved as monotherapy and in combination with standard-of-care regimens for multiple myeloma. In clinical studies, the median durations of...
20.
Mateos M, San-Miguel J, Goldschmidt H, Sonneveld P, Dimopoulos M, Heeg B, et al.
Leuk Lymphoma
. 2019 Nov;
61(3):680-690.
PMID: 31686561
For patients with newly diagnosed multiple myeloma (NDMM) who are transplant ineligible, bortezomib-melphalan-prednisone (VMP) demonstrated superior efficacy based on the VISTA trial. In subsequent trials, twice-weekly bortezomib was limited to...